Phase 2 Oesophageal Cancer Trial, Recruiting NCT07405151 Sponsor: Merck Sharp & Dohme LLC Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 2 Oesophageal Cancer Trial, Recruiting

NCT07405151
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a type of esophageal cancer called squamous cell carcinoma that cannot be removed by surgery and has either spread locally or to other parts of the body (confirmed by a biopsy or cell test)
  • Your cancer has gotten worse after trying 1 or 2 previous treatments for this condition
  • Your cancer can be measured on scans or tests
  • If you have HIV, it is well-controlled with medication
  • Your organs (such as kidneys, liver, and heart) are working well enough as determined by your doctor

Who may not be able to join:

  • Your esophageal cancer has been confirmed to be a different type, called adenocarcinoma or adenosquamous carcinoma
  • You have fluid build-up around your lungs, heart, or abdomen that is difficult to control and needs frequent draining or medical treatment
  • You have a significant eye or cornea condition
  • You have had a stroke, mini-stroke, or another blood clot event affecting an artery in the past 6 months
  • You have HIV and also have a history of a condition called Kaposi's sarcoma or Multicentric Castleman's Disease
  • You have heart or blood vessel disease that is not well controlled
  • You have or are being treated for another cancer that has been active or required treatment in the past 3 years
  • Your cancer has spread to your brain or the lining around your brain and spine in an active way
  • You have ever had a lung condition called interstitial lung disease (ILD) or pneumonitis, except for a specific type caused by radiation that did not need steroid treatment (confirm with trial site)
  • You currently have an active infection that requires treatment through a drip or medication (other than certain permitted treatments)
  • You have serious lung problems caused by other illnesses, including conditions such as severe asthma, severe COPD, blood clots in the lungs within the last 3 months, restricted lung function, autoimmune diseases affecting the lungs, or if you have had a lung removed or currently need extra oxygen to breathe

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Medical Director, Merck Sharp & Dohme LLC

Phone: 1-888-577-8839

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
27 March 2026
Est. completion
12 June 2027

Where this trial is recruiting

🇧🇷 Brazil 🇨🇳 China 🇨🇿 Czechia 🇯🇵 Japan 🇳🇴 Norway 🇰🇷 South Korea 🇨🇭 Switzerland 🇹🇼 Taiwan 🇹🇭 Thailand 🇺🇸 United States

Primary endpoints

Objective Response Rate (ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov